Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 20.72 · gapped below the open, then crossed back over prior close. High/low 20.97 at 12:15 pm ET, 20.40 at 9:45 am ET.
Sarepta Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On February 13, 2025, we entered into a $600.0 million revolving credit agreement with JPMorgan Chase Bank, N.A., as administrative agent and as collateral agent, the lenders party thereto, and Sarepta Therapeutics Investments, Inc., a Delaware corporation and wholly owned subsidiary (the "Credit Agreement").”
FILING10-K0001193125-26-084144cik 0000873303
“In September 2022, we issued $1,150.0 million aggregate principal amount of 2027 Notes, pursuant to that certain indenture dated as of September 16, 2022, between us, as issuer, and U.S. Bank National Association, as trustee, including $20.0 million of 2027 Notes issued to the Michael A. Chambers Living Trust in a private placement.”
FILING10-K0001193125-26-084144cik 0000873303
“The decrease in short-term manufacturing commitments is primarily driven by a supplemental letter agreement (the "Letter Agreement") entered into with Catalent in August 2025 to address certain financial and operational matters related to the ELEVIDYS Suspension.”
FILING10-K0001193125-26-084144cik 0000873303
“In accordance with the Roche Collaboration Agreement, the parties agreed to enter into a supply agreement in order for us to supply Roche with clinical and commercial batches of ELEVIDYS (the "Roche Supply Agreement").”
FILING10-K0001193125-26-084144cik 0000873303
“SRP-1003 We have a variety of pending patent applications related to SRP-1003, which is licensed from Arrowhead, including applications directed to compositions of matter that would, if issued, expire 2043.”
FILING10-K0001193125-26-084144cik 0000873303
“In September 2022, we issued $1,150.0 million aggregate principal amount of 2027 Notes, pursuant to that certain indenture dated as of September 16, 2022, between us, as issuer, and U.S. Bank National Association, as trustee, including $20.0 million of 2027 Notes issued to the Michael A. Chambers Living Trust in a private placement.”
FILING10-K0001193125-26-084144cik 0000873303
“Our cost of sales (excluding amortization of in-licensed rights) consists of inventory costs that relate to sales of our products and the related overhead costs and royalty payments primarily to BioMarin and UWA for our PMO Products and to Nationwide for ELEVIDYS.”
FILING10-K0001193125-26-084144cik 0000873303
“• $120.2 million decrease in manufacturing expenses primarily due to costs associated with the termination of the development, commercial manufacturing and supply agreement (the "Thermo Agreement") related to Brammer Bio MA, LLC, an affiliate of Thermo Fisher Scientific, Inc. ("Thermo") in 2024, with no similar activity in 2025;”
FILING10-K0001193125-26-084144cik 0000873303
“11,723,986 United States Composition of Matter 2037 Nationwide”
FILING10-K0001193125-26-084144cik 0000873303
“Amortization of in-licensed rights relates to the agreements we entered into with UWA, Nationwide, BioMarin and Parent Project Muscular Dystrophy in April 2013, December 2016, July 2017 and May 2018, respectively.”
FILING10-K0001193125-26-084144cik 0000873303
“U.S. RE47,769 United States Composition of Matter 2029 UWA”
FILING10-K0001193125-26-084144cik 0000873303
“• $78.8 million decrease in manufacturing-related deposits and prepaids primarily due to the use of raw materials and services previously prepaid with Catalent and Aldevron.”
FILING10-K0001193125-26-084144cik 0000873303
Watchlist prices, news filtered to it, and its next report on your desk.
Sarepta Therapeutics, Inc. has 10 disclosed suppliers and 2 disclosed customers. Each one is named in an SEC filing, either Sarepta Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
SRPT (Sarepta Therapeutics, Inc.) has 10 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ARWR −11.26%, in healthcare.